Welcome to our dedicated page for Envoy Medical SEC filings (Ticker: COCHW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This Envoy Medical, Inc. (COCHW) filings page provides access to the company’s SEC disclosures, including current reports on Form 8-K that describe material events, securities offerings, and other significant developments. Envoy Medical is a hearing health company focused on medical technologies for hearing loss, with a single reportable segment related to hearing and revenue from Esteem FI-AMEI implants and replacement components.
Key filing types for Envoy Medical, Inc. include current reports on Form 8-K that outline material definitive agreements, unregistered sales of equity securities, and other events. Recent 8-K filings describe a securities purchase agreement for a registered direct offering of Class A common stock, a concurrent private placement of warrants, and the issuance of placement agent warrants. These documents detail purchase prices, warrant exercise terms, ownership limitations, lock-up periods, and restrictions on variable rate transactions.
Envoy Medical’s filings also reference an effective shelf registration statement on Form S-3 and obligations to file a registration statement on Form S-1 to register the resale of shares issuable upon exercise of certain warrants. For investors tracking warrant activity, the filings describe redeemable warrants trading under the COCHW symbol on The Nasdaq Stock Market LLC, as well as private and placement agent warrants issued in connection with offerings.
With AI-powered tools layered on top of these filings, users can quickly identify the core terms of Envoy Medical’s financing transactions, understand the structure of its warrant instruments, and see how registration rights and stockholder approval requirements are defined. Real-time updates from EDGAR, combined with AI-generated highlights, help clarify long-form disclosures so readers can focus on the provisions that matter most for Envoy Medical, Inc.’s capital structure and hearing-focused business.
Envoy Medical, Inc. announced that its Board of Directors appointed Charles S. McKhann as a Class I director, with his initial term running until the company’s 2027 annual meeting of stockholders. In connection with his appointment, the Board size increased from six to seven members.
Mr. McKhann also joined the Board’s Compensation Committee and was granted stock options to purchase 100,000 shares of Class A Common Stock at an exercise price of $0.72 per share, vesting in 36 equal monthly installments. The Board determined that he qualifies as an independent director under Nasdaq and SEC standards.
Envoy Medical, Inc. director Chas McKhann received a grant of stock options covering 100,000 shares of Class A common stock. The options have an exercise price of $0.72 per share and expire on April 15, 2036.
Beginning May 15, 2026, these options vest pro rata on the 15th of each month over 36 consecutive months. After this grant, McKhann holds stock options for 100,000 underlying shares directly.
Envoy Medical, Inc. director Chas McKhann received a grant of stock options covering 100,000 shares of Class A common stock. The options have an exercise price of $0.72 per share and expire on April 15, 2036.
Beginning May 15, 2026, these options vest pro rata on the 15th of each month over 36 consecutive months. After this grant, McKhann holds stock options for 100,000 underlying shares directly.
Envoy Medical, Inc. director Chas McKhann filed an initial Form 3 statement of beneficial ownership for the company’s common stock. The filing shows no reported purchases, sales, derivative exercises, gifts, tax withholdings, restructurings, or other transactions, and no current derivative positions listed.
Envoy Medical, Inc. director Chas McKhann filed an initial Form 3 statement of beneficial ownership for the company’s common stock. The filing shows no reported purchases, sales, derivative exercises, gifts, tax withholdings, restructurings, or other transactions, and no current derivative positions listed.
Envoy Medical, Inc. filed Amendment No. 1 to its annual report for the year ended December 31, 2025 to correct a typographical error in the consent of Grant Thornton LLP, its independent registered public accounting firm. The amendment also includes updated officer certifications under Section 302 of the Sarbanes-Oxley Act and makes no other changes to the original report.
The company reported an aggregate market value of approximately $12.7 million for Class A common stock held by non-affiliates as of its most recently completed fiscal quarter, and had 76,881,110 Class A shares outstanding as of March 20, 2026.
Envoy Medical, Inc. filed Amendment No. 1 to its annual report for the year ended December 31, 2025 to correct a typographical error in the consent of Grant Thornton LLP, its independent registered public accounting firm. The amendment also includes updated officer certifications under Section 302 of the Sarbanes-Oxley Act and makes no other changes to the original report.
The company reported an aggregate market value of approximately $12.7 million for Class A common stock held by non-affiliates as of its most recently completed fiscal quarter, and had 76,881,110 Class A shares outstanding as of March 20, 2026.
Envoy Medical is asking stockholders to approve several items at its May 12, 2026 annual meeting, including electing two Class III directors and ratifying EisnerAmper LLP as new auditor after dismissing Grant Thornton, whose prior reports included substantial doubt about the company’s ability to continue as a going concern and cited material weaknesses in internal control.
Stockholders will vote on an advisory say-on-pay proposal, a major amendment to the 2023 Equity Incentive Plan adding 6,000,000 shares for a total of 10,000,000, and an amendment to the Employee Stock Purchase Plan increasing its reserve by 1,200,000 to 1,500,000 shares. They are also asked to approve, under Nasdaq Listing Rule 5635(d), the exercisability of warrants issued in a February 12, 2026 financing, covering up to 123,750,000 shares of Class A common stock, which could significantly increase the company’s share count if fully exercised.
Envoy Medical is asking stockholders to approve several items at its May 12, 2026 annual meeting, including electing two Class III directors and ratifying EisnerAmper LLP as new auditor after dismissing Grant Thornton, whose prior reports included substantial doubt about the company’s ability to continue as a going concern and cited material weaknesses in internal control.
Stockholders will vote on an advisory say-on-pay proposal, a major amendment to the 2023 Equity Incentive Plan adding 6,000,000 shares for a total of 10,000,000, and an amendment to the Employee Stock Purchase Plan increasing its reserve by 1,200,000 to 1,500,000 shares. They are also asked to approve, under Nasdaq Listing Rule 5635(d), the exercisability of warrants issued in a February 12, 2026 financing, covering up to 123,750,000 shares of Class A common stock, which could significantly increase the company’s share count if fully exercised.
Envoy Medical, Inc. reported that its audit committee dismissed Grant Thornton LLP as its independent registered public accounting firm on March 25, 2026 and appointed EisnerAmper LLP to audit the fiscal year ending December 31, 2026.
Grant Thornton’s audit reports for the years ended December 31, 2025 and 2024 contained explanatory paragraphs expressing substantial doubt about Envoy Medical’s ability to continue as a going concern, but were not otherwise qualified or modified. The company states there were no disagreements with Grant Thornton and no reportable events other than previously disclosed material weaknesses in internal control over financial reporting.
Envoy Medical, Inc. reported that its audit committee dismissed Grant Thornton LLP as its independent registered public accounting firm on March 25, 2026 and appointed EisnerAmper LLP to audit the fiscal year ending December 31, 2026.
Grant Thornton’s audit reports for the years ended December 31, 2025 and 2024 contained explanatory paragraphs expressing substantial doubt about Envoy Medical’s ability to continue as a going concern, but were not otherwise qualified or modified. The company states there were no disagreements with Grant Thornton and no reportable events other than previously disclosed material weaknesses in internal control over financial reporting.
Envoy Medical reported full year 2025 results showing it is still early-stage but making strategic progress. Net revenue was $241,000, slightly up from $225,000, while operating expenses of $22.5 million and other items drove a net loss of $23.8 million and a net loss attributable to common stockholders of $28.7 million, or $1.23 per share.
The company strengthened its balance sheet by extinguishing about $32 million of related-party term loan debt, supported by a $27.9 million deemed capital contribution. Total liabilities were $20.3 million and stockholders’ deficit improved to $12.2 million as of December 31, 2025, with cash of $3.7 million.
Operationally, Envoy advanced its fully implanted Acclaim cochlear implant program, receiving FDA approval to expand its pivotal trial to its final stage in 2025 and subsequently completing enrollment. After year-end it closed what it describes as a transformational capital raise led by institutional healthcare investors, positioning it to continue development toward a planned PMA submission.
Envoy Medical reported full year 2025 results showing it is still early-stage but making strategic progress. Net revenue was $241,000, slightly up from $225,000, while operating expenses of $22.5 million and other items drove a net loss of $23.8 million and a net loss attributable to common stockholders of $28.7 million, or $1.23 per share.
The company strengthened its balance sheet by extinguishing about $32 million of related-party term loan debt, supported by a $27.9 million deemed capital contribution. Total liabilities were $20.3 million and stockholders’ deficit improved to $12.2 million as of December 31, 2025, with cash of $3.7 million.
Operationally, Envoy advanced its fully implanted Acclaim cochlear implant program, receiving FDA approval to expand its pivotal trial to its final stage in 2025 and subsequently completing enrollment. After year-end it closed what it describes as a transformational capital raise led by institutional healthcare investors, positioning it to continue development toward a planned PMA submission.
Envoy Medical, Inc. has regained compliance with the Nasdaq Capital Market’s continued listing standards. Nasdaq confirmed that the company now meets Listing Rule 5550(b)(2) after previously receiving a notice in February 2025 for not maintaining the required $35 million Market Value of Listed Securities.
The company attributes its renewed compliance to strategic financing initiatives that substantially strengthened its balance sheet and will remain under a one-year discretionary panel monitor starting February 12, 2026. Envoy Medical states it believes it has an achievable plan to stay in compliance and continue trading on Nasdaq under the symbol COCH.
Envoy Medical, Inc. has regained compliance with the Nasdaq Capital Market’s continued listing standards. Nasdaq confirmed that the company now meets Listing Rule 5550(b)(2) after previously receiving a notice in February 2025 for not maintaining the required $35 million Market Value of Listed Securities.
The company attributes its renewed compliance to strategic financing initiatives that substantially strengthened its balance sheet and will remain under a one-year discretionary panel monitor starting February 12, 2026. Envoy Medical states it believes it has an achievable plan to stay in compliance and continue trading on Nasdaq under the symbol COCH.
Patel Mona Chetan reported open-market purchase transactions in a Form 4 filing for COCH. The filing lists transactions totaling 812,500 shares at a weighted average price of $0.40 per share. Following the reported transactions, holdings were 187,500 shares.
Patel Mona Chetan reported open-market purchase transactions in a Form 4 filing for COCH. The filing lists transactions totaling 812,500 shares at a weighted average price of $0.40 per share. Following the reported transactions, holdings were 187,500 shares.